Connor, Clark & Lunn Investment Management (CC&L)’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-1,647
| Closed | -$16K | – | 1269 |
|
|
2022
Q2 | $16K | Sell |
1,647
-12,069
| -88% | -$117K | ﹤0.01% | 1017 |
|
|
2022
Q1 | $163K | Buy |
13,716
+1,853
| +16% | +$22K | ﹤0.01% | 958 |
|
|
2021
Q4 | $387K | Buy |
11,863
+1,532
| +15% | +$50K | ﹤0.01% | 850 |
|
|
2021
Q3 | $462K | Buy |
10,331
+2,726
| +36% | +$122K | ﹤0.01% | 786 |
|
|
2021
Q2 | $414K | Buy |
+7,605
| New | +$414K | ﹤0.01% | 820 |
|
|
2019
Q3 | – | Sell |
-2,884
| Closed | -$267K | – | 1108 |
|
|
2019
Q2 | $267K | Sell |
2,884
-9,002
| -76% | -$833K | ﹤0.01% | 849 |
|
|
2019
Q1 | $1.09M | Sell |
11,886
-370
| -3% | -$33.8K | 0.01% | 514 |
|
|
2018
Q4 | $683K | Buy |
12,256
+390
| +3% | +$21.7K | ﹤0.01% | 638 |
|
|
2018
Q3 | $1.41M | Buy |
11,866
+1,600
| +16% | +$191K | 0.01% | 507 |
|
|
2018
Q2 | $1.05M | Buy |
10,266
+4,535
| +79% | +$463K | 0.01% | 603 |
|
|
2018
Q1 | $744K | Buy |
5,731
+4,270
| +292% | +$554K | ﹤0.01% | 519 |
|
|
2017
Q4 | $142K | Buy |
+1,461
| New | +$142K | ﹤0.01% | 741 |
|